BACKGROUND: The excess mortality associated with depressive disorders has been most often attributed to risks for suicide but diverse findings indicate that depressive disorders also increase risks for cardiovascular (CV) mortality. Among the possible mediators is the hypothalamic-pituitary-adrenal (HPA)-axis hyperactivity that characterizes many cases of relatively severe depressive disorder and severity is characteristic of psychotic depressive disorder. METHODS: The following describes a 17-year mortality follow-up of 54 patients with Research Diagnostic Criteria (RDC) psychotic major depression or schizoaffective, mainly affective, depression. All had baseline assessments that included a 1mg dexamethasone suppression test with post-dexamethasone samples at 8 a.m., 4 p.m. and 11 p.m. RESULTS: Regression analyses showed that both greater age and higher maximum post-dexamethasone cortisol concentrations predicted deaths due to CV causes (t=4.01, p<0.001 and t=3.03, p=0.004, respectively). The 4 who died from CV disease had a mean (SD) post-dexamethasone cortisol concentration of 18.0 (6.0)microg/dl while the mean (SD) value for the remaining 50 patients was 7.6 (6.6)microg/dl (t=3.03, df=53, p=0.004). Regression analyses showed the 11 p.m. post-dexamethasone value to be predictive of suicide (t=2.05, p=0.048). CONCLUSIONS: Conclusions should be tentative because an earlier follow-up of a more heterogeneous, but larger, sample did not find a relationship between DST results and CV mortality, and because only 4 CV deaths occurred in the present study. HPA-axis hyperactivity is probably only one of a number of factors that link depressive disorder to CV mortality.
BACKGROUND: The excess mortality associated with depressive disorders has been most often attributed to risks for suicide but diverse findings indicate that depressive disorders also increase risks for cardiovascular (CV) mortality. Among the possible mediators is the hypothalamic-pituitary-adrenal (HPA)-axis hyperactivity that characterizes many cases of relatively severe depressive disorder and severity is characteristic of psychotic depressive disorder. METHODS: The following describes a 17-year mortality follow-up of 54 patients with Research Diagnostic Criteria (RDC) psychotic major depression or schizoaffective, mainly affective, depression. All had baseline assessments that included a 1mg dexamethasone suppression test with post-dexamethasone samples at 8 a.m., 4 p.m. and 11 p.m. RESULTS: Regression analyses showed that both greater age and higher maximum post-dexamethasonecortisol concentrations predicted deaths due to CV causes (t=4.01, p<0.001 and t=3.03, p=0.004, respectively). The 4 who died from CV disease had a mean (SD) post-dexamethasonecortisol concentration of 18.0 (6.0)microg/dl while the mean (SD) value for the remaining 50 patients was 7.6 (6.6)microg/dl (t=3.03, df=53, p=0.004). Regression analyses showed the 11 p.m. post-dexamethasone value to be predictive of suicide (t=2.05, p=0.048). CONCLUSIONS: Conclusions should be tentative because an earlier follow-up of a more heterogeneous, but larger, sample did not find a relationship between DST results and CV mortality, and because only 4 CV deaths occurred in the present study. HPA-axis hyperactivity is probably only one of a number of factors that link depressive disorder to CV mortality.
Authors: T O Harris; S Borsanyi; S Messari; K Stanford; S E Cleary; H M Shiers; G W Brown; J Herbert Journal: Br J Psychiatry Date: 2000-12 Impact factor: 9.319
Authors: S A Everson; D E Goldberg; G A Kaplan; R D Cohen; E Pukkala; J Tuomilehto; J T Salonen Journal: Psychosom Med Date: 1996 Mar-Apr Impact factor: 4.312
Authors: A Aromaa; R Raitasalo; A Reunanen; O Impivaara; M Heliövaara; P Knekt; V Lehtinen; M Joukamaa; J Maatela Journal: Acta Psychiatr Scand Suppl Date: 1994
Authors: A Carlo Altamura; Marta Serati; Alessandra Albano; Riccardo A Paoli; Ira D Glick; Bernardo Dell'Osso Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-02-18 Impact factor: 5.270
Authors: H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai Journal: J Psychopharmacol Date: 2008-09-18 Impact factor: 4.153
Authors: Qian Li; Nicole R Sullivan; Carrie E McAllister; Louis D Van de Kar; Nancy A Muma Journal: Psychoneuroendocrinology Date: 2012-12-05 Impact factor: 4.905
Authors: Nicholas H Neufeld; Antonia N Kaczkurkin; Aristeidis Sotiras; Benoit H Mulsant; Erin W Dickie; Alastair J Flint; Barnett S Meyers; George S Alexopoulos; Anthony J Rothschild; Ellen M Whyte; Linda Mah; Jay Nierenberg; Matthew J Hoptman; Christos Davatzikos; Theodore D Satterthwaite; Aristotle N Voineskos Journal: Neuropsychopharmacology Date: 2020-02-28 Impact factor: 8.294